by Anand Patadiya | Oct 2, 2024
BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has entered into a formal research collaboration with the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Ankyra is developing a novel anchored...
by Anand Patadiya | Oct 2, 2024
BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer. Dr. Elassal will fill the role formerly...
by Anand Patadiya | Oct 2, 2024
Data to be presented during Society for Immunotherapy of Cancer 37th Annual Meeting BOSTON — Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that new, preclinical data highlighting the...
by Anand Patadiya | Oct 2, 2024
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research. Dr. Emens is an experienced...
by Anand Patadiya | Oct 2, 2024
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*. The collaboration will...
